Inventor · disambiguated record
Feng Ren
Also filed as: REN FENG
23 granted patents·29 pending applications·9 citations·filing 2008–2025
91Inventor score
Files withINSILICO MEDICINE IP LTD23GLAXOSMITHKLINE IP DEV LTD11SHANGHAI MEDICILON INC6DENG GUANGHUI34B TECH BEIJING CO LIMITED1
Top patents by PatentIndex Score
52 records- 0192US11731987B2Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Aug 22, 2023·3 cites·30 claims
- 0290US11780854B2Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Oct 10, 2023·1 cites·29 claims
- 0386US11731944B2SARS-CoV-2 inhibitors for treating coronavirus infectionsINSILICO MEDICINE IP LTD·Filed 2023·Granted Aug 22, 2023·1 cites·27 claims
- 0481US12209101B2Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Jan 28, 2025·0 cites·14 claims
- 0581US12071443B2Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Aug 27, 2024·0 cites·21 claims
- 0679US12091406B2Lysine acetyltransferase 6A (KAT6A) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Sep 17, 2024·0 cites·20 claims
- 0778US2025034132A1Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2022·Application pending·0 cites
- 0873US11999713B2Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Jun 4, 2024·0 cites·20 claims
- 0973US2024109880A1Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 1072US2024025860A1Sars-cov-2 inhibitors for treating coronavirus infectionsINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 1171US12077538B2Diacylglycerol kinase (DGK) alpha inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Sep 3, 2024·0 cites·20 claims
- 1270US11034696B2Compounds for inhibiting LRRK2 kinase activityGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Jun 15, 2021·1 cites·18 claims
- 1368US2024051958A1Diacylglycerol kinase (dgk) alpha inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 1467US10975081B2Substituted fused pyrazole compounds and their use as LRRK2 inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Granted Apr 13, 2021·1 cites·18 claims
- 1565US2025042890A1METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOFINSILICO MEDICINE IP LTD·Filed 2022·Application pending·0 cites
- 1664US12103915B2TEAD inhibitors and methods of uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Granted Oct 1, 2024·0 cites·26 claims
- 1764US2025340569A1Inhibitors of kif18a and uses thereofINSILICO MEDICINE IP LTD·Filed 2025·Application pending·0 cites
- 1863US2025188094A1Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 1963US2025163077A1Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 2063US2025197405A1Heteroaromatic compounds as pkmyt1 inhibitors and use thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 2162US2025145624A1Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 2261US8389508B2Heterocyclic compoundsDENG GUANGHUI·Filed 2011·Granted Mar 5, 2013·2 cites·9 claims
- 2361US2025145632A1Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in MedicineINSILICO MEDICINE IP LTD·Filed 2022·Application pending·0 cites
- 2460US2025214967A1Fak degraders, pharmaceutical compositions, and therapeutic applicationsBERRYBIO SHANGHAI LTD·Filed 2023·Application pending·0 cites
- 2560US2025136596A1Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 2657US12378252B2Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicineSHANGHAI MEDICILON INC·Filed 2019·Granted Aug 5, 2025·0 cites·3 claims
- 2757US2025214990A1Diacylglycerol kinase (dgk) alpha inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 2857US2025064843A1Method and medicament for treating amyotrophic lateral sclerosis4B TECH BEIJING CO LIMITED·Filed 2022·Application pending·0 cites
- 2955US12486229B2Indole derivative and application thereofSHANGHAI MEDICILON INC·Filed 2021·Granted Dec 2, 2025·0 cites·3 claims
- 3055US2025101019A1Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereofINSILICO MEDICINE IP LTD·Filed 2023·Application pending·0 cites
- 3147US2011124671A1Spiroindenes and spiroindanes as modulators of chemokine receptorsBUDZIK BRIAN W·Filed 2008·Application pending·0 cites
- 3246US12404276B2Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseasesSHANGHAI MEDICILON INC·Filed 2019·Granted Sep 2, 2025·0 cites·4 claims
- 3346US8217028B21,2,4-oxadiazole indole compoundsCASTRO PINEIRO JOSE LUIS·Filed 2009·Granted Jul 10, 2012·0 cites·4 claims
- 3445US10336719B21-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Jul 2, 2019·0 cites·15 claims
- 3543US12377452B2Method for extracting and separating salt alkali from saline alkali soil and soil improvementUNIV TARIM·Filed 2023·Granted Aug 5, 2025·0 cites·10 claims
- 3641US12391696B2Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicineSHANGHAI MEDICILON INC·Filed 2019·Granted Aug 19, 2025·0 cites·2 claims
- 3740US2020002323A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 3839US10858367B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Dec 8, 2020·0 cites·18 claims
- 3939US2020392158A1Inhibitors of leucine rich repeat kinase 2GLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 4038US2022259213A1Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicineSHANGHAI MEDICILON INC·Filed 2019·Application pending·0 cites
- 4138US2021130339A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 4238US2022259215A1Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicineSHANGHAI MEDICILON INC·Filed 2019·Application pending·0 cites
- 4338US2013012491A1Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonistsGLAXO GROUP LTD·Filed 2011·Application pending·0 cites
- 4437US2019389850A1CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 4536US10106515B21-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Oct 23, 2018·0 cites·12 claims
- 4635US9868724B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Jan 16, 2018·0 cites·21 claims
- 4734US9902715B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Feb 27, 2018·0 cites·21 claims
- 4834US2012283297A1Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonistsBAILEY JAMES·Filed 2010·Application pending·0 cites
- 4928US2012101124A11,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonistsLIN XICHEN·Filed 2010·Application pending·0 cites
- 5028US2012094979A1Thiazole or thiadizaloe derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonistsBAILEY JAMES MATTHEW·Filed 2010·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Feng Ren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →